BIOGEN INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
BIOGEN INC. (BIIB) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $80.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-04.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2015-02-04
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2013-03-31 was $700.00K.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2011-03-31 was $6.90M, a 305.88% increase year-over-year.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2010-03-31 was $1.70M.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2014 was $80.00K, a 98.75% decline from fiscal 2013.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2013 was $6.39M, a 117.48% increase from fiscal 2012.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2012 was $2.94M, a 2110.53% increase from fiscal 2011.
- BIOGEN INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2011 was $133.00K, a 97.90% decline from fiscal 2010.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|
| 2014-12-31 | $80.00K 10-K · filed 2015-02-04 | ||
| 2013-12-31 | $6.39M 10-K · filed 2015-02-04 | ||
| 2013-03-31 | $700.00K 10-Q · filed 2013-04-25 | ||
| 2012-12-31 | $2.94M 10-K · filed 2015-02-04 | ||
| 2011-12-31 | $133.00K 10-K · filed 2013-02-05 | ||
| 2011-03-31 | $6.90M 10-Q · filed 2011-04-21 | ||
| 2010-12-31 | $6.34M 10-K · filed 2013-02-05 | ||
| 2010-03-31 | $1.70M 10-Q · filed 2011-04-21 | ||
| 2009-12-31 | $4.14M 10-K · filed 2012-02-03 | -$379.00K 10-K · filed 2010-02-09 | |
| 2008-12-31 | -$1.12M 10-K · filed 2010-02-09 | ||
| 2007-12-31 | -$3.98M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |